Nivolumab With Standard of Care Chemotherapy for the First Line Treatment of Peripheral T Cell Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Nivolumab (Primary) ; Prednisone (Primary) ; Vincristine (Primary)
- Indications Anaplastic large cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 08 Nov 2018 Status changed from not yet recruiting to recruiting.
- 05 Sep 2018 Planned initiation date changed from 1 Aug 2018 to 1 Nov 2018.
- 18 Jul 2018 New trial record